Compare IMUX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | ASRT |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 76.0M |
| IPO Year | 2013 | 2004 |
| Metric | IMUX | ASRT |
|---|---|---|
| Price | $14.08 | $23.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $36.00 | $18.00 |
| AVG Volume (30 Days) | 230.1K | ★ 306.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.61 |
| 52 Week High | $15.77 | $23.49 |
| Indicator | IMUX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 83.19 |
| Support Level | $0.74 | $11.05 |
| Resistance Level | $15.77 | N/A |
| Average True Range (ATR) | 1.37 | 0.03 |
| MACD | -0.41 | -0.20 |
| Stochastic Oscillator | 60.31 | 86.96 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.